Parkinson's Disease Research

Parkinson's disease (PD) is a degenerative disease of the central nervous system that often impairs motor skills, speech, and other functions. Symptoms of the disease include resting tremor, bradykinesia and rigidity. The primary symptoms are the result of decreased stimulation of the motor cortex by the basal ganglia, normally caused by the insufficient formation and action of dopamine, which is produced in the dopaminergic neurons of the brain. Symptoms of the disease appear once 50-80% of dopamine neurons have died. Parkinson's disease is both chronic and progressive.

Parkinson's Disease Research Products Targets

Products for Parkinson's Disease Research - Page 73

  1. Cat.No. Product Name Information/Activity
  2. BCC7865 Cinnabarinic acid 606-59-7 Cinnabarinic acid chemical structure
  3. BCC7045 (RS)-3,4-DCPG 176796-64-8 (RS)-3,4-DCPG chemical structure
  4. BCC7012 (S)-3,4-DCPG 201730-11-2 (S)-3,4-DCPG chemical structure
  5. BCC7652 NPEC-caged-(S)-3,4-DCPG 1257323-85-5 NPEC-caged-(S)-3,4-DCPG chemical structure
  6. BCC6578 O-Phospho-L-serine O-Phospho-L-serine is the immediate precursor to L-serine in the serine synthesis pathway, and an agonist at the group III mGluR receptors (mGluR4, mGluR6, mGluR7, and mGluR8); O-Phospho-L-serine also acts as a weak antagonist for mGluR1 and a potent antagonist for mGluR2. O-Phospho-L-serine chemical structure
  7. BCC6975 (RS)-PPG (RS)-PPG is a potent and selective agonist for group III mGluRs. The EC50s of 5.2 μM, 4.7 μM, 185 μM, and 0.2 μM for hmGluR4a, hmGluR6, hmGluR7b, and hmGluR8a, respectively. Anticonvulsive and neuroprotective activity. (RS)-PPG chemical structure
  8. BCC7615 VU 0155041 1093757-42-6 VU 0155041 chemical structure
  9. BCC7642 VU 0155041 sodium salt 1259372-69-4 VU 0155041 sodium salt chemical structure
  10. BCC7616 Z-Cyclopentyl-AP4 103439-17-4 Z-Cyclopentyl-AP4 chemical structure
  11. BCC6872 CPPG CPPG ((RS)-CPPG) is a potent group II/III mGlu receptor antagonist. CPPG exhibits some selectivity (approximately 20 fold) for group III (IC50=2.2 nM) over group II (IC50=46.2 nM) mGlu receptors in the rat cerebral cortex. CPPG has weak effects at group I mGlu receptors. CPPG chemical structure

Items 721 to 730 of 752 total